In-depth structural characterization of Kadcyla® (ado-trastuzumab emtansine) and its biosimilar candidate

The biopharmaceutical industry has become increasingly focused on developing biosimilars as less expensive therapeutic products. As a consequence, the regulatory approval of 2 antibody-drug conjugates (ADCs), Kadcyla® and Adcetris® has led to the development of biosimilar versions by companies locat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:MAbs
Main Authors: Chen, Liuxi, Wang, Lan, Shion, Henry, Yu, Chuanfei, Yu, Ying Qing, Zhu, Lei, Li, Meng, Chen, Weibin, Gao, Kai
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2016
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058630/
https://ncbi.nlm.nih.gov/pubmed/27380163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2016.1204502
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados